Answers are grounded in this paper and cite their sources.
Analysis reveals disparities in pharmacy costs for treatment modalities in colorectal cancer patients, indicating financial implications.
Estimated differences in pharmacy prescription costs before and after CRC diagnosis for non-mCRC versus mCRC patients, stratified by treatment modality in the first year
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: